findmyKOL

Toni Choueiri, MD

Enriched profile

Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute

ORCID↗NPI↗
✓ Full profile
RegionBoston, MA · NortheastSpecialtyMedical OncologyFocusRenal cell carcinoma treatment+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2015–2026

Toni Choueiri is Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 2,494 publications with 128,964 citations (h-index 152); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Toni K. Choueiri is Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. The public record shows 2,494 publications with 128,964 citations (h-index 152), centered on Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 12 registered clinical trials, 7 NIH-funded awards (2015–2026).

  • Most recent indexed publication: 2026 · The New England journal of medicine
  • Top research focus: Renal cell carcinoma treatment
  • 12 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Kidney Cancer / RCC8 trialsKidney Neoplasms4 trialsBladder / Urothelial Cancer2 trialsNeoplasms by Site1 trialUrologic Neoplasms1 trialCarcinoma, Transitional Cell1 trial

Research focus

OpenAlex concept fingerprint
Renal cell carcinoma treatmentCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsCancer Genomics and DiagnosticsRenal and related cancers

Drugs & molecules

across trials, industry payments and publications
Opdivogeneric · NivolumabClinical trials1Industry payments5Publications20Cabometyxgeneric · CabozantinibClinical trials1Industry payments10Publications8Welireggeneric · BelzutifanClinical trials1Industry payments7Publications4Keytrudageneric · PembrolizumabClinical trials—Industry payments28Publications7SunitinibClinical trials3Industry payments—Publications15IpilimumabClinical trials2Industry payments—Publications10Fotivdageneric · TivozanibClinical trials1Industry payments6Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments4Publications3AtezolizumabClinical trials1Industry payments—Publications4BevacizumabClinical trials1Industry payments—Publications3DocetaxelClinical trials1Industry payments—Publications2GozetotideClinical trials—Industry payments4Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments58E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments22Exelixis Inc.Clinical trials—Industry payments11AVEO Pharmaceuticals, Inc.Clinical trials—Industry payments6Dana-Farber Cancer InstituteClinical trials5Industry payments—Gilead Sciences, Inc.Clinical trials—Industry payments5Merck Sharp & Dohme CorporationClinical trials—Industry payments5Eisai Inc.Clinical trials—Industry payments4Caris MPI, Inc.Clinical trials—Industry payments3Toni Choueiri, MDClinical trials3Industry payments—AstraZenecaClinical trials2Industry payments—AstraZeneca Pharmaceuticals LPClinical trials—Industry payments2Telix PharmaceuticalsClinical trials—Industry payments2Alkermes, Inc.Clinical trials—Industry payments1Amgen Inc.Clinical trials—Industry payments1AstraZeneca UK LimitedClinical trials—Industry payments1EMD Serono, Inc.Clinical trials—Industry payments1Ipsen Biopharm LimitedClinical trials—Industry payments1Ipsen Pharma SASClinical trials—Industry payments1Janssen Global Services, LLCClinical trials—Industry payments1National Cancer Institute (NCI)Clinical trials1Industry payments—Patrick Ott, MD, PhDClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
2,494publications

Distinct works indexed by OpenAlex, matched via ORCID; 134 in PubMed.

128,964citations

Total citations across indexed works.

152h-index

Hirsch index (OpenAlex). i10-index 907.

Clinical & industry

trials, payments and federal funding
12clinical trials

Investigator role on registered studies.

View trials ↓
18companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
7NIH grants · 2015–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record
  • As FDA ODAC member

    voted on/commented on drug approval matters (e.g., recommended PTEN expression ≥90% cutoff for capivasertib indication due to toxicity concerns; voted on camizestrant for HR+/HER2- breast cancer)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:

All 12 trial records: search, sort and filter.Explore →

Industry payments

18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 33 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Kinase inhibitor100%
    Inlyta100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

7 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:

All 18 award records: search, sort and filter.Explore →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 134 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    The Immune Landscape of Cancer
    6,200 citations2018
    doi.org ↗
  2. 02
    Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
    5,896 citations2015
    doi.org ↗
  3. 03
    Post-acute COVID-19 syndrome
    5,025 citations2021
    doi.org ↗
  4. 04
    Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
    4,647 citations2018
    doi.org ↗
  5. 05
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    3,395 citations2017
    doi.org ↗
All 2,494 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Sabina Signoretti584David F. McDermott500David A. Braun389Rana R. McKay362Robert J. Motzer359Eliezer M. Van Allen328Wanling Xie297Ziad Bakouny283Brian I. Rini278Lauren C. Harshman274Bradley A. McGregor267Joaquim Bellmunt260Thomas Denize249Sumanta K. Pal245Michael B. Atkins244Ulka N. Vaishampayan234Talal El Zarif225Laurence Albigès194Valisha Shah192Renée Maria Saliby190Guru Sonpavde185Gwo‐Shu Mary Lee178Frede Donskov173Elizabeth R. Plimack172Wenxin Xu171Xiao X. Wei165Thomas Powles165Quoc‐Dien Trinh164Ronan Flippot159Paul L. Nguyen158Miriam Ficial155Amin H. Nassar151Bernard Escudier144Christian Kollmannsberger135Laure Hirsch134Jae‐Lyun Lee134John A. Steinharter132Matthew L. Freedman130Maxine Sun127David J. Kwiatkowski125

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/toni-choueiri-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/toni-choueiri-924b9614b

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/profile/Toni-Choueiri

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/DrChoueiri

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • Instagram

    instagram.com/choueirit

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗

Mentions by others

where others cite or feature them
  • Other

    themedicinementors.libsyn.com/the-true-mark-of-success-with-dr-toni-choueiri

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →themedicinementors.libsyn.com ↗
  • Instagram

    instagram.com/curetoday/reel/DAQqvqRvZcf

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • Instagram

    instagram.com/danafarber/p/CqTBEowufVF

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • X / Twitter

    X/Twitter handle @DrChoueiri

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗
  • LinkedIn

    LinkedIn profile - Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Hematology/Medical Oncology Fellowship

    Cleveland Clinic Foundation

    2007
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Board Certified

    Internal Medicine

    2007
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
  • Board Certified

    Medical Oncology

    2007
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Internal Medicine Residency

    Cleveland Clinic Foundation

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • MD

    Saint Joseph University Faculty of Medicine (Beirut, Lebanon), 1993-2000

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗

Editorial & leadership roles

journal and society appointments
  • Member

    ASCO Board of Directors (Undesignated Member seat), 2024-2028

    2028
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
  • Member

    FDA Oncologic Drugs Advisory Committee (ODAC), term 8/28/2023-6/30/2027

    2027
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fda.gov ↗
  • Board Member

    KidneyCan

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗
  • Past Chairman

    Medical and Scientific Steering Committee, Kidney Cancer Association

    2018
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Past President

    Medical Staff, Dana-Farber Cancer Institute

    2018
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Chair

    ASCO Plenary Series

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
  • Co-founder

    ASCO International Medical Graduates (IMG) Community of Practice

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
  • Member

    National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Member

    National Cancer Institute GU Steering Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Co-founder

    International Metastatic RCC Database Consortium (IMDC)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Medical Director

    International Strategic Initiatives, Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Co-leader

    Kidney Cancer Program, Dana-Farber/Harvard Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Attending Physician

    Medical Oncology, Brigham and Women's Hospital

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗

Media & interviews

press, podcasts and appearances
  • Video interview series

    UroToday

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
  • Regular video contributor/author

    OncLive (multiple interviews on RCC treatment developments)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • Interview

    CancerNetwork - 'How New Data Impact the Standard of Care for RCC'

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
  • Jimmy Fund podcast interview

    'Jones and Keefe' show, discussing kidney cancer with patient John Warner

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →goodpods.com ↗
  • Q&A feature

    Outcomes4Me - 'What's on the horizon for kidney cancer?'

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →outcomes4me.com ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.